We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the medicines.ie website. Find out more

Pfizer Healthcare Ireland

9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24,
Telephone: +353 1 467 6500
Fax: +353 1 467 6501
Medical Information Direct Line: 1 800 633 363
Medical Information Website: http://www.pfizermedicalinformation.ie
Patient Information Leaflet last updated on medicines.ie: 12/10/2017
PIL Toviaz Prolonged-Release Tablets 4mg & 8mg

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 12/10/2017 and displayed until Current
Reasons for adding or updating:
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision
  • Improved presentation of PIL
Updated on 05/08/2016 and displayed until 12/10/2017
Reasons for adding or updating:
  • Change to date of revision
  • Improved electronic presentation
Updated on 03/07/2015 and displayed until 05/08/2016
Reasons for adding or updating:
  • Change to date of revision
  • Change to MA holder contact details
Updated on 01/10/2014 and displayed until 03/07/2015
Reasons for adding or updating:
  • Change to MA holder contact details
  • Change to date of revision
Updated on 18/10/2012 and displayed until 01/10/2014
Reasons for adding or updating:
  • Introduction of new pack/pack size
Updated on 27/03/2012 and displayed until 18/10/2012
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to side-effects
  • Change to drug interactions
  • Change to information about pregnancy or lactation
  • Change to how the medicine works
  • Change to further information section
  • Change to date of revision
  • Change to improve clarity and readability
  • Change of special precautions for disposal
Updated on 28/10/2011 and displayed until 27/03/2012
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to date of revision
Updated on 01/04/2011 and displayed until 28/10/2011
Reasons for adding or updating:
  • Change to side-effects
  • Change to drug interactions
  • Change to further information section
  • Change to date of revision
Updated on 24/02/2011 and displayed until 01/04/2011
Reasons for adding or updating:
  • Change to further information section
Updated on 09/07/2010 and displayed until 24/02/2011
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 17/07/2009 and displayed until 09/07/2010
Reasons for adding or updating:
  • Introduction of new pack/pack size
Updated on 02/04/2009 and displayed until 17/07/2009
Reasons for adding or updating:
  • Improved electronic presentation
Updated on 16/03/2009 and displayed until 02/04/2009
Reasons for adding or updating:
  • Addition of marketing authorisation holder
Updated on 21/01/2009 and displayed until 16/03/2009
Reasons for adding or updating:
  • Change to date of revision
  • Introduction of new pack/pack size
Updated on 01/09/2008 and displayed until 21/01/2009
Reasons for adding or updating:
  • New PIL for new product

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Fesoterodine Fumarate